These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2849447)

  • 1. Omeprazole, SCH 28080 and doxepin differ in their characteristics to inhibit H+/K+-ATPase driven proton accumulation by parietal cell membrane vesicles.
    Beil W; Staar U; Schünemann P; Sewing KF
    Biochem Pharmacol; 1988 Dec; 37(23):4487-93. PubMed ID: 2849447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted thieno[3,4-d]imidazoles, a novel group of H+/K(+)-ATPase inhibitors. Differentiation of their inhibition characteristics from those of omeprazole.
    Beil W; Staar U; Sewing KF
    Eur J Pharmacol; 1990 Oct; 187(3):455-67. PubMed ID: 1963594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mechanism of action of the gastric microsomal (H+ + K+)-ATPase inhibitors SCH 32651 and SCH 28080.
    Scott CK; Sundell E; Castrovilly L
    Biochem Pharmacol; 1987 Jan; 36(1):97-104. PubMed ID: 3026407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.
    Morii M; Takata H; Fujisaki H; Takeguchi N
    Biochem Pharmacol; 1990 Feb; 39(4):661-7. PubMed ID: 2154989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helicobacter pylori augments the acid inhibitory effect of omeprazole on parietal cells and gastric H(+)/K(+)-ATPase.
    Beil W; Sewing KF; Busche R; Wagner S
    Gut; 2001 Feb; 48(2):157-62. PubMed ID: 11156634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of H+,K+-ATPase by methyl(E)-2-(3,4-dimethoxystyryl)-benzimidazole-4-carboxylate (ALE-36).
    Yamamoto O; Tanaka H; Ueda F; Kimura K
    Scand J Gastroenterol Suppl; 1989; 162():178-81. PubMed ID: 2556788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell.
    Wallmark B; Brändström A; Larsson H
    Biochim Biophys Acta; 1984 Dec; 778(3):549-58. PubMed ID: 6095911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Possible mechanisms for (H+ + K+)-ATPase inhibition by proton pump inhibitors, omeprazole, lansoprazole and SCH 28080].
    Nagaya H; Satoh H
    Nihon Rinsho; 1992 Jan; 50(1):26-32. PubMed ID: 1311786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
    Mattsson JP; Väänänen K; Wallmark B; Lorentzon P
    Biochim Biophys Acta; 1991 Jun; 1065(2):261-8. PubMed ID: 1647821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omeprazole and SCH 28080 inhibit acid secretion by the turtle urinary bladder.
    Graber ML; Devine P
    Ren Physiol Biochem; 1993; 16(5):257-67. PubMed ID: 7694339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole.
    Sabolić I; Brown D; Verbavatz JM; Kleinman J
    Am J Physiol; 1994 Jun; 266(6 Pt 2):F868-77. PubMed ID: 7517642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gastric H+,K+-ATPase: the site of action of omeprazole.
    Sachs G; Wallmark B
    Scand J Gastroenterol Suppl; 1989; 166():3-11. PubMed ID: 2557669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
    Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
    Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of (H+ + K+)-ATPase by omeprazole in isolated gastric vesicles requires proton transport.
    Lorentzon P; Jackson R; Wallmark B; Sachs G
    Biochim Biophys Acta; 1987 Feb; 897(1):41-51. PubMed ID: 3026477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of H+K+ATPase by SCH 28080 and SCH 32651.
    Scott CK; Sundell E
    Eur J Pharmacol; 1985 Jun; 112(2):268-70. PubMed ID: 2993001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of gastric K+/H+-ATPase by acid-activated 2-((2-pyridylmethyl)sulphinyl)benzimidazole products.
    Beil W; Hannemann H; Mädge S; Sewing KF
    Eur J Pharmacol; 1987 Jan; 133(1):37-45. PubMed ID: 3030771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omeprazole: mode of action and effect on acid secretion in animals.
    Wallmark B
    Scand J Gastroenterol Suppl; 1989; 166():12-8. PubMed ID: 2557668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+ + K+)-ATPase.
    Keeling DJ; Malcolm RC; Laing SM; Ife RJ; Leach CA
    Biochem Pharmacol; 1991 Jun; 42(1):123-30. PubMed ID: 1648919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of (H+ + K+)-ATPase and H+ accumulation in hog gastric membranes by trifluoperazine, verapamil and 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate.
    Im WB; Blakeman DP; Mendlein J; Sachs G
    Biochim Biophys Acta; 1984 Feb; 770(1):65-72. PubMed ID: 6320882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the mechanism of action of A80915A, a semi-naphthoquinone natural product, as an inhibitor of gastric (H(+)-K+)-ATPase.
    Dantzig AH; Minor PL; Garrigus JL; Fukuda DS; Mynderse JS
    Biochem Pharmacol; 1991 Oct; 42(10):2019-26. PubMed ID: 1683772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.